drugset / Trial / NCT00637871
Casodex - Nolvadex Combination
RandomizedParallel-groupDouble-blindTreatment
Summary
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex. The aim of the study is to assess the optimal dose of nolvadex which will reduce the breast tissue adverse effects without reducing the efficacy of Casodex.
Timeline
- Start
- 2002-11
- Primary completion
- 2005-06
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |
| Comparator | Tamoxifen | Small molecule | — | Oral |